Interview with Anna Portela, CEO of the startup Xenopat
Xenopat offers the most innovative tools to those researchers and companies dedicated to the development of new drugs against cancer. It is a public-private company, a spin-off of the Catalan Institute of Oncology (ICO), the Bellvitge Biomedical Research Institute (IDIBELL) and the Bellvitge University Hospital (HUB).
We had the opportunity to interview Anna Portela, CEO of this great initiative.
Anna explains that with their proposal they are committed to counseling in personalized medicine, based on pilot studies that lead to conclusions about the treatment of tumors in a way adapted to each patient.
In the coming year, Xenopat wants to carry out a pilot study between 50 and 100 patients, to demonstrate the response to their treatments and start marketing their services.
The team of Xenopat evaluates very positively the acceleration program of Santalucia, since it offers them a great opportunity to access the knowledge of professionals with extensive experience in the health sector.
Anna Portela's advice to entrepreneurs like her is to put maximum enthusiasm into their projects and to enjoy the “road”.
To learn more about Xenopat you can follow them on their social networks:
